The objectives of the project are: - To develop an innovative technology for extracting data on antibody-antigen binding from scientific publications to create databases for training machine learning models. - To introduce an innovative service to the market that uses computational methods to identify candidates for new biological drugs. The R&D work in the project will encompass three key stages: Stage 1 - Creation of language models to extract key information on antibody binding from vast amounts of scientific literature. Stage 2 - Integration of the extracted data to construct a novel model capable of proposing antibodies for specific target molecules. Stage 3 - Transformation of this model into a service enabling collaboration with pharmaceutical companies to jointly develop new biological drugs. The project represents a paradigm shift in antibody therapy, moving from experimental methods to in silico approaches. It also carries significant potential to accelerate the discovery and development of innovative solutions for treating a wide range of diseases, fostering collaboration between academia and industry to achieve substantial progress in healthcare. The outcome of the R&D work will be a market-ready technology called ASE (Antibody Specificity Extraction), addressing identified needs in the pharmaceutical market. The primary recipients of the planned service will be companies developing antibody-based drugs. Project value: PLN 4,649,360.49 EU Funds contribution: PLN 3,525,767.25 #FunduszeUE #FunduszeEuropejskie